Epigraph:
Every human life is precious and sacred and saving one is like saving the whole of humanity. (Al Quran 5:32/33)
The Muslim Times has the best collection of articles for the war against Covid 19, especially the vaccines.
These 3 Covid-19 vaccines have been in the news. Here’s what you need to know about them
By Theresa Waldrop, CNN
(CNN) The US government is pouring billions into Covid-19 vaccines, and candidates from three companies are moving along quickly: Moderna, Pfizer and Novavax.
Here’s what you need to know about them.
These are among the dozens of Covid-19 vaccines in trials around the world as researchers rush to find a way to stop the pandemic.
To help speed the process, the US government’s Operation Warp Speed is providing some funding for those three and five others — vaccine candidates the US Department of Health and Human Services calls “the most promising.”
Face masks have become our new normal, and with these masks, you can make sure you’re doing even more good than usual.
Operation Warp Speed’s goal is to have 300 million doses of a vaccine that’s safe and effective by January 2021.
While the Phase 1 trial results are promising, the proof will be in the results of the final, large Phase 3 trials. If a vaccine candidate makes it through that, it will go to the US Food and Drug Administration for approval.
Phase 1 trials involve testing the vaccine in a small group of people to see if it’s safe and if it’s effective. Phase 2 trials involve a larger group and often involve various potential doses. Phase 3 trials are a final stage before seeking approval and look for safety, efficacy and optimal dosing. For coronavirus, they are all scheduled to involve 30,000 people.
Read further about Moderna, Pfizer and Novavax vaccines
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
For the latest health news from BBC, Please click here
Novavax starting human trial of its vaccine in Australia
Kaiser Permanente launches first coronavirus vaccine trial
Corona Fear’s Cure: Chanting from the Bible and the Quran
Can You Chant from the Bible or the Quran to Bliss and Happiness?
Japanese flu drug ‘clearly effective’ in treating coronavirus, says China
Synthetic antibodies might offer a quick coronavirus treatment
The Four Possible Timelines for Life Returning to Normal
The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic
Coronavirus: TB Vaccination Trial Started in Melbourne, Australia
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
All of humanity are intimate neighbors: Coronavirus proves it once again
Praise be to God for the Miracle of Our Immune System
USA: 15-minute coronavirus test is here
Does the Ordinary Soap Kill Coronavirus?
Here’s a list of disinfectants you can use against coronavirus
For the number of cases and epidemiology in each country go to: WorldOMeters
DAILY NEW CASES AND DEATHS IN US, CDC SITE
Coronavirus Vaccine Tracker – The New York Times
Categories: The Muslim Times, Vaccine
Reblogged this on Alexanders' Blog.
Investors should consider the risk of a successful coronavirus vaccine unsettling markets by sparking a sell-off in bonds and rotation out of technology into cyclical stocks, according to Goldman Sachs Group Inc.
The increased probability of an approved vaccine by the end of November is underpriced by equity markets, wrote strategists including Kamakshya Trivedi in a note Wednesday. Over the next few months, the ramifications of the U.S. election and the evolution of the virus — in part as schools reopen — are also likely to be key drivers of the market, they said.
Approval of a vaccine could “challenge market assumptions both about cyclicality and about eternally negative real rates,” the team wrote, adding such a scenario may support steeper yield curves, traditional cyclicals and banks, while challenging the leadership of technology stocks.
If this happened along with a change in the U.S. administration, emerging market equities could benefit “if trade policy risks diminish while U.S. tax risks rise,” according to the note.
https://www.bloomberg.com/news/articles/2020-08-06/goldman-says-time-to-think-about-a-shift-in-market-leadership?srnd=premium&sref=eGA8az79